Therapeutic Classification: opioid analgesics
Pharmacologic Classification: opioid agonists antagonists
High Alert
Absorption: Well absorbed after IM and SL use; 4665% absorbed with buccal use; 15% of transdermal dose absorbed through skin; IV administration results in complete bioavailability.
Distribution: Extensively distributed to tissues; CNS concentration is 1525% of plasma.
Protein Binding: 96%.
Half-Life: IV: 23 hr; Buccal: 27 hr; Transdermal: 26 hr; SL: 37 hr; Subdermal: 2448 hr; SUBQ: 4360 days.
(analgesia)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
IM | 15 min | 60 min | 6 hr‡ |
IV | rapid | less than 60 min | 6 hr‡ |
SL | unknown | unknown | unknown |
Transdermal | unknown | unknown | 7 days |
Buccal | unknown | unknown | unknown |
SUBQ | unknown | unknown | unknown |
‡45 hr in children.
Contraindicated in:
Use Cautiously in:
CV: hypertension, hypotension, palpitations, QT interval prolongation
Derm: sweating, clammy feeling, erythema, pruritus, rash
EENT: blurred vision, diplopia, miosis (high doses)
Endo: adrenal insufficiency
GI: nausea, constipation, dry mouth, HEPATOTOXICITY, ileus, vomiting
Local: injection site reactions
Neuro: confusion, dysphoria, hallucinations, sedation, dizziness, euphoria, floating feeling, headache, unusual dreams
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)
Misc: allodynia, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, AND BRONCHOSPASM), opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance
Drug-drug:
Drug-Natural Products:
Analgesia
Hepatic Impairment
Hepatic Impairment
Treatment of Opioid Use Disorder
Hepatic Impairment
Lab Test Considerations:
Toxicity and Overdose:
IV Administration: